CLINICAL ROLE -
Implementing Glofitamab-GemOx in Practice: STARGLO Insights
Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.
You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment
Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML
CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.
Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression free at 5 years without maintenance.
A Season of Growth: Reflecting on Summer, Connection, and the Power of Mentorship
August marks a pivotal time for oncology pharmacy, blending transitions, celebrations, and new beginnings as professionals prepare for the upcoming season.
From Botanicals to Blood Counts: Exploring Pharmacist-Led Cancer Care Strategies